BioMarin Pharmaceutical (BMRN) Competitors

BioMarin Pharmaceutical (NASDAQ:BMRN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Is BMRN or ALNY more profitable?

BioMarin Pharmaceutical has a net margin of 14.96% compared to Alnylam Pharmaceuticals' net margin of -12.37%. BioMarin Pharmaceutical's return on equity of 9.91% beat Alnylam Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	14.96%	9.91%	7.65%
Alnylam Pharmaceuticals	-12.37%	N/A	-6.83%

Do insiders and institutionals hold more shares of BMRN or ALNY?

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 0.9% of BioMarin Pharmaceutical shares are owned by company insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Does the media prefer BMRN or ALNY?

In the previous week, Alnylam Pharmaceuticals had 3 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 19 mentions for Alnylam Pharmaceuticals and 16 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 1.55 beat Alnylam Pharmaceuticals' score of 1.12 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	11 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Alnylam Pharmaceuticals	11 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, BMRN or ALNY?

BioMarin Pharmaceutical has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500.

Does the MarketBeat Community favor BMRN or ALNY?

BioMarin Pharmaceutical received 414 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.34% of users gave Alnylam Pharmaceuticals an outperform vote while only 74.59% of users gave BioMarin Pharmaceutical an outperform vote.

Company	Underperform	Outperform
BioMarin Pharmaceutical	Outperform Votes 1582 74.59%	Underperform Votes 539 25.41%
Alnylam Pharmaceuticals	Outperform Votes 1168 76.34%	Underperform Votes 362 23.66%

Do analysts rate BMRN or ALNY?

BioMarin Pharmaceutical presently has a consensus target price of $93.45, indicating a potential upside of 63.15%. Alnylam Pharmaceuticals has a consensus target price of $319.58, indicating a potential upside of 4.89%. Given BioMarin Pharmaceutical's higher probable upside, equities research analysts clearly believe BioMarin Pharmaceutical is more favorable than Alnylam Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.74
Alnylam Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.77

Which has preferable valuation and earnings, BMRN or ALNY?

BioMarin Pharmaceutical has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$2.95B	3.72	$167.65M	$2.69	21.29
Alnylam Pharmaceuticals	$2.35B	16.92	-$278.16M	-$2.09	-145.78

Summary

BioMarin Pharmaceutical beats Alnylam Pharmaceuticals on 11 of the 18 factors compared between the two stocks.